May 5, 2020
Vifor Pharma’s partner Akebia with positive cardiovascular outcomes program testing vadadustat,
Akebia’s vadadustat, an investigational oral HIF-PHI, achieves primary efficacy and cardiovascular safety endpoints.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: cardiovascular
June 19, 2019
Natural ingredients show beneficial effects on cardiovascular health and sports performance
Euromed, a Spain-based producer of standardized herbal extracts and natural active substances for pharmaceutical, nutraceutical and cosmetic industries, said Wednesday that, according to a recently published randomised, double-blind, placebo-controlled study, supplementation with Euromed’s natural extracts Pomanox™ and Mediteanox™ could help to maintain a healthy blood pressure, endothelial function and levels of circulating oxidised low-density lipoprotein cholesterol (oxLDL).
March 1, 2018
Amarin Corporation’s cardiovascular study is nearing completion
Amarin Corporation’s REDUCE-IT cardiovascular study is nearing end, as the patients enrolled in it have begun the final study-related visits.
June 23, 2017
LEADER trial data included in Novo Nordisks Saxenda in Europe
Novo Nordisk got the right from the European Medicines Agency’s committee (EMA) to include data from the LEADER trial to Saxenda to the results from the trial showed the long-term effects of Victoza for type 2 diabetes and established cardiovascular disease patients.
March 20, 2017
AstraZeneca’s diabetes drug reduces the risk of heart failure
AstraZeneca has reported results of the first large real-world evidence study of its kind evaluating the risk of hospitalisation for heart failure and death from any cause in patients with type-2 diabetes (T2D) receiving treatment with a newer class of diabetes medicines, SGLT-2 inhibitors (SGLT-2i).
January 6, 2017
Novartis and Ionis team on cardiovascular treatments
Novartis and Ionis Pharmaceuticals with its affiliate Akcea Therapeutics have signed an agreement for licensing two novel treatments for reducing cardiovascular risk in patients with high levels of lipoproteins known as Lp(a) and ApoCIII.
November 1, 2016
Pfizer to discontinue two ongoing cardiovascular studies
Pfizer announced today the discontinuation of the global clinical development program for bococizumab…
February 19, 2016
AstraZeneca’s Brilique OK for marketing in EU
The European Commission has granted to AstraZeneca marketing authorisation for Brilique (ticagrelor) at a new 60mg dose for the treatment of patients who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event.
September 17, 2015
Jardiance reduces cardiovascular death rate in T2D patients
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly reported that the Company’s Jardiance (empagliflozin) had reduced the risk of the…